Jerry Jones Negotiates With Prescott, Elliott, Cooper, Golden Tate’s Fertility Medication, Roc Nation Partnership

FOOTBALL

Dallas Cowboys’ owner and general manager Jerry Jones is trying to figure out how to keep his offensive star players happy with new lucrative deals.  Jones offered Quarterback Dak Prescott, running back Ezekiel Elliott, and receiver Amari Cooper salaries that would rank in the top five of their positions, but the three are still negotiating. Jones expressed his disappointment in the situation and how he needed to fit their salaries within the confines of the salary cap.  He said, “It’s not like me going out here and buying something that I have to decide whether I want to just spend to have that. That’s not it at all. It’s that I’ve got to realize that I can let a DeMarcus Ware out of here because I don’t have enough money because I paid it to too many others. That’s happened to me, and I don’t want it to happen again. And, we’ve got some top talent here.”

New York Giants newly acquired wide receiver Golden Tate (who was signed as a result of the team losing Odell Beckham Jr. to the Cleveland Browns) lost his appeal of a four-game suspension for violating the League’s Performance Enhancing Substance Policy.  Tate claims he tested positive as a result of prescribed fertility medication he was taking in the hopes he and his wife could have a third child. Tate won’t be able to take the field until October 6th against the Minnesota Vikings.

The NFL reached a multi-year agreement with music, entertainment company Roc Nation, founded by rapper and business executive Shawn “Jay-Z” Carter.  In an attempt to “nurture and strengthen community through football and music, including through the NFL’s Inspire Change initiative”, Roc Nation will advise the NFL on their selection of artists for major events including the Super Bowl. The company will also collaborate on “production, promotion, and marketing of live music events” and potentially producing artists podcasts.

 

 

 

 

 

Share
No comments

No comments yet. Be the first.

Leave a reply